Chinese General Practice ›› 2023, Vol. 26 ›› Issue (06): 704-710.DOI: 10.12114/j.issn.1007-9572.2022.0581
• Precision Medication·Renal Anemia • Previous Articles Next Articles
Received:
2022-07-21
Revised:
2022-10-11
Published:
2023-02-20
Online:
2022-10-20
Contact:
LI Qing
About author:
通讯作者:
李青
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0581
第一作者 | 发表年份(年) | 国家 | NCT | 单中心/多中心 | 临床研究阶段 | 样本量(例) | 男性〔n(%)〕 | 年龄(岁) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
试验组 | 对照组 | 试验组 | 对照组 | 试验组 | 对照组 | ||||||
AKIZAWA[ | 2020 | 日本 | NCT02952092 | 多中心 | Ⅲ期 | 150 | 151 | 101(67.3) | 107(70.9) | 64.6±11.7 | 64.9±10.1 |
AKIZAWA[ | 2019 | 日本 | NCT01964196 | 多中心 | Ⅲ期 | 13 | 43 | 10(76.9) | 26(60.5) | 64.4±8.7 | 61.9±10.6 |
CHEN[ | 2019 | 中国 | NCT02652806 | 多中心 | Ⅲ期 | 204 | 100 | 126(61.8) | 58(58.0) | 47.6±11.7 | 51.0±11.8 |
CHEN[ | 2017 | 中国 | NCT01596855 | 多中心 | Ⅱ期 | 74 | 22 | 45(60.4) | 13(59.1) | 50.0±12.8 | 53.8±10.0 |
PROVENZANO[ | 2016 | 美国 | NCT01147666 | 多中心 | Ⅱ期 | 41 | 13 | 27(66.0) | 9(69.0) | 55.8±13.4 | 59.5±10.1 |
PROVENZANO[ | 2016 | 美国 | NCT01147666 | 多中心 | Ⅱ期 | 67 | 23 | 45(67.0) | 14(61.0) | 56.9±12.1 | 57.0±11.6 |
第一作者 | 基线血红蛋白(g/dl) | 干预措施 | 罗沙司他剂量 | 干预时间(周) | 结局指标 | ||||||
试验组 | 对照组 | 试验组 | 对照组 | ||||||||
AKIZAWA[ | 11.00±0.56 | 11.00±0.60 | 罗沙司他 | ESAs | 70 mg、100 mg,TIW | 24 | ①②③④⑤⑥⑦⑧ | ||||
AKIZAWA[ | 9.35±0.75 | 10.85±0.54 | 罗沙司他 | ESAs | 50 mg、70 mg,TIW;70 mg、100 mg,TIW | 24 | ①②③④⑤⑦⑧ | ||||
CHEN[ | 10.40±0.70 | 10.50±0.70 | 罗沙司他 | ESAs | 100 mg(体质量45~<60 kg)、120 mg(体质量≥60 kg) | 26 | ①②③④⑤⑥⑦⑧ | ||||
CHEN[ | 10.80±0.70 | 10.60±1.00 | 罗沙司他 | ESAs | 1.1~1.8 mg/kg、1.5~3.0 mg/kg、1.7~2.3 mg/kg,TIW | 6 | ①②③④⑤⑥⑦⑧ | ||||
PROVENZANO[ | 11.30±0.60 | 11.50±0.60 | 罗沙司他 | ESAs | 1.0 mg/kg、1.5 mg/kg、1.8 mg/kg、2.0 mg/kg,TIW | 6 | ①②③⑤⑥⑦⑧ | ||||
PROVENZANO[ | 11.20±0.70 | 11.20±1.00 | 罗沙司他 | ESAs | 1.0 mg/kg、1.5 mg/kg、1.8 mg/kg、2.0 mg/kg,TIW | 19 | ①②③⑤⑥⑦⑧ |
Table 1 Characteristics of studies included in meta-analysis
第一作者 | 发表年份(年) | 国家 | NCT | 单中心/多中心 | 临床研究阶段 | 样本量(例) | 男性〔n(%)〕 | 年龄(岁) | |||
---|---|---|---|---|---|---|---|---|---|---|---|
试验组 | 对照组 | 试验组 | 对照组 | 试验组 | 对照组 | ||||||
AKIZAWA[ | 2020 | 日本 | NCT02952092 | 多中心 | Ⅲ期 | 150 | 151 | 101(67.3) | 107(70.9) | 64.6±11.7 | 64.9±10.1 |
AKIZAWA[ | 2019 | 日本 | NCT01964196 | 多中心 | Ⅲ期 | 13 | 43 | 10(76.9) | 26(60.5) | 64.4±8.7 | 61.9±10.6 |
CHEN[ | 2019 | 中国 | NCT02652806 | 多中心 | Ⅲ期 | 204 | 100 | 126(61.8) | 58(58.0) | 47.6±11.7 | 51.0±11.8 |
CHEN[ | 2017 | 中国 | NCT01596855 | 多中心 | Ⅱ期 | 74 | 22 | 45(60.4) | 13(59.1) | 50.0±12.8 | 53.8±10.0 |
PROVENZANO[ | 2016 | 美国 | NCT01147666 | 多中心 | Ⅱ期 | 41 | 13 | 27(66.0) | 9(69.0) | 55.8±13.4 | 59.5±10.1 |
PROVENZANO[ | 2016 | 美国 | NCT01147666 | 多中心 | Ⅱ期 | 67 | 23 | 45(67.0) | 14(61.0) | 56.9±12.1 | 57.0±11.6 |
第一作者 | 基线血红蛋白(g/dl) | 干预措施 | 罗沙司他剂量 | 干预时间(周) | 结局指标 | ||||||
试验组 | 对照组 | 试验组 | 对照组 | ||||||||
AKIZAWA[ | 11.00±0.56 | 11.00±0.60 | 罗沙司他 | ESAs | 70 mg、100 mg,TIW | 24 | ①②③④⑤⑥⑦⑧ | ||||
AKIZAWA[ | 9.35±0.75 | 10.85±0.54 | 罗沙司他 | ESAs | 50 mg、70 mg,TIW;70 mg、100 mg,TIW | 24 | ①②③④⑤⑦⑧ | ||||
CHEN[ | 10.40±0.70 | 10.50±0.70 | 罗沙司他 | ESAs | 100 mg(体质量45~<60 kg)、120 mg(体质量≥60 kg) | 26 | ①②③④⑤⑥⑦⑧ | ||||
CHEN[ | 10.80±0.70 | 10.60±1.00 | 罗沙司他 | ESAs | 1.1~1.8 mg/kg、1.5~3.0 mg/kg、1.7~2.3 mg/kg,TIW | 6 | ①②③④⑤⑥⑦⑧ | ||||
PROVENZANO[ | 11.30±0.60 | 11.50±0.60 | 罗沙司他 | ESAs | 1.0 mg/kg、1.5 mg/kg、1.8 mg/kg、2.0 mg/kg,TIW | 6 | ①②③⑤⑥⑦⑧ | ||||
PROVENZANO[ | 11.20±0.70 | 11.20±1.00 | 罗沙司他 | ESAs | 1.0 mg/kg、1.5 mg/kg、1.8 mg/kg、2.0 mg/kg,TIW | 19 | ①②③⑤⑥⑦⑧ |
[1] |
|
[2] |
|
[3] |
|
[4] |
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
孟松,朱晶晶,李少华,等. 授权教育结合思维导图对维持性血液透析重度肾性贫血患者的影响[J]. 国际移植与血液净化杂志,2021,19(6):43-45. DOI:10.3760/cma.j.cn115399-20210421-06012.
|
[15] | |
[16] |
|
[17] |
KDOQI, NATIONAL KIDNEY FOUNDATION. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease[J]. Am J Kidney Dis,2006,47(5 Suppl 3):S11-145. DOI:10.1053/j.ajkd.2006.03.010.
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
|
[26] |
|
[27] |
|
[28] |
李辉锋,毛永炎. 罗沙司他治疗慢性肾脏病透析患者合并肾性贫血的效果和安全性[J]. 中国实用医刊,2021,48(22):99-102. DOI:10.3760/cma.j.cn115689-20210820-02744.
|
[1] | XIE Xuemei, GAO Jing, BAI Dingxi, LU Xianying, HE Jiali, LI Yue. Current Status of Polypharmacy in the Elderly and Its Influencing Factors: a Meta-analysis [J]. Chinese General Practice, 2023, 26(35): 4394-4403. |
[2] | WANG Yue, CHEN Qing, LIU Lurong. Detection Rate of Depression and Its Influencing Factors in Chinese Elderly: a Meta-analysis [J]. Chinese General Practice, 2023, 26(34): 4329-4335. |
[3] | WANG Zhe, DONG Zhihao, ZHENG Hao, KONG Wencheng, ZHANG Yukuan, ZHANG Qiuyue, HAN Jing. Construction of Optimized Treatment Plan of Acupuncture for Migraine Based on Entropy Weight-TOPSIS Method [J]. Chinese General Practice, 2023, 26(34): 4336-4342. |
[4] | JIAN Qiufeng, XU Ronghua, YAO Qian, ZHOU Yuanyuan. A Meta-analysis of the Prevalence and Influencing Factors of Post-stroke Cognitive Impairment in Chinese Elderly Patients [J]. Chinese General Practice, 2023, 26(32): 4070-4079. |
[5] | JIA Yu, ZHOU Zitong, CAO Xuehua, HU Wanqin, XIANG Feng, XIONG Langyu, WANG Xiaoxia. Incidence of Perimenopausal Syndrome in Chinese Women Aged 40 to 65 Years: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4080-4088. |
[6] | LI Jixin, QIU Linjie, REN Yan, WANG Wenru, LI Meijie, ZHANG Jin. The Correlation of Dietary Inflammatory Index with Overweight, Obesity and Abdominal Obesity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(32): 4089-4097. |
[7] | HE Jingyi, WANG Fang, SHUI Xiaoling, LI Ling, LIANG Qian. Efficacy of Non-pharmacological Interventions to Improve Perimenopausal Insomnia Symptoms: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(31): 3963-3974. |
[8] | WANG Jiaxin, ZHAO Yali. Domestic and International Assessment Tools for Medical Teamwork: a Systematic Review [J]. Chinese General Practice, 2023, 26(31): 3951-3962. |
[9] | ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832. |
[10] | ZHANG Dongli, SHEN Chong, ZHANG Weichuan, CHEN Haibin, ZHAO Jianjun. Efficacy and Safety of Programmed Death-1/Programmed Death-1 Ligand Inhibitors in the Treatment of Renal Cell Cancer: a Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3815-3822. |
[11] | HE Li, ZHANG Yifan, SHEN Xuechun, SUN Yan, ZHAO Yang. Prevalence Trends of Multimorbidity among Residents in Mainland China: a Meta-analysis [J]. Chinese General Practice, 2023, 26(29): 3599-3607. |
[12] | REN Yanfeng, LIU Shimeng, TAO Ying, CHEN Yingyao. A Systematic Review of Medication Preferences for Patients with Depression Based on Discrete Choice Experiment and Best-worst Scaling [J]. Chinese General Practice, 2023, 26(28): 3559-3564. |
[13] | LIN Yang, WANG Fang, WANG Han, WU Rong, WANG Yao, XU Ziyao, WANG Xu, WANG Yanding. Prevalence of Frailty in Elderly Patients with Comorbidity: a Meta-analysis [J]. Chinese General Practice, 2023, 26(25): 3185-3193. |
[14] | DUAN Yuxia, LI Zhen, ZHANG Siqi, FANG Zhixue, QIN Yuelan. Effect of Patient Decision Aids in the Diagnosis and Treatment of Colorectal Cancer: a Systematic Review [J]. Chinese General Practice, 2023, 26(25): 3194-3201. |
[15] | GUO Yinning, MIAO Xueyi, JIANG Xiaoman, XU Ting, XU Qin. Effects of Protein Supplementation on Muscle Mass, Strength, and Physical Function in Frail/Pre-frail Older Adults: a Meta-analysis [J]. Chinese General Practice, 2023, 26(23): 2854-2863. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||